జర్నల్ ఆఫ్ క్లినికల్ అండ్ ఎక్స్‌పెరిమెంటల్ ట్రాన్స్‌ప్లాంటేషన్

నైరూప్య

Induction Therapy: Comparison between Poly and Monoclonal Antibodies

Talmoudi A, Azzabi A, Sahtout W, Mrabet S, Guedri Y, Zallama D, Toumi S, Fradi A, Sabri F, Amor S and Achour A

Objective: Compare the effects of 2 molecules as induction treatment in renal transplantation (RT): polyclonal antibodies (rATG or thymoglobulin) versus a monoclonal antibody antagonist of interleukin 2 receptors (basiliximub) in terms of occurrence of episodes of rejection, delayed graft function, graft loss, and the occurrence of infectious and neoplastic complications.
Patients and methods: A retrospective study involving 191 patients transplanted from 2007 to 2016 with a minimum follow-up of 3 months at department of nephrology, dialysis and transplantation Sahloul Sousse Tunisia. The induction treatment consists of the administration of a monoclonal antibody for 67 patients group 1 (G1) and polyclonal antibodies (anti-thymocyte anti-thymocyte globulin or thymoglobulin) for 124 patients group 2 (G2). In maintenance, patients were treated with ciclosporin or tacrolimus combined with MMF and corticosteroids or MMF alone with corticosteroids.
Results: We included 191 transplant patients with mean age of 33.13 ± 13.04 years. The occurrence of episodes of rejection was more frequent in patients treated with rATG (21.77% in G2 versus 14.92% in G1) but without significant difference (p =0.253). The delay of occurrence of rejection was shorter in the G1. The uni-varied study showed that the occurrence of pneumopathies (p=0.005, OR=6.626, IC [1.503-29.20]), urinary tract infections (p=0.020, OR=2.044, CI [1.115-3.748]), cystitis (p=0.038, OR=1.918, CI [1.032-3.564]), CMV infections (p=0.04, OR=2.567, CI [0.996-6.615]) and digestive infections (p=0.035, OR=4.472, CI [0.991-20.186]) are significantly observed with rATG treatment. In multi-variate analysis only pneumopathies (p=0.014, CI [0.034-0.681]) and urinary tract infections (p=0.04, CI [0.277- 0.969]) were significantly frequent with ATG treatment. Neoplastic complications occurred exclusively in G2. We found no significant difference for delayed graft function and graft loss in both groups.